• What's New
  • News Releases
  • Apr. 12, 2017 (PDF/81KB)R&D
    Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder (ADHD)
  • Apr. 07, 2017 (PDF/87KB)Licensing
    Sumitomo Dainippon Pharma Announces Partnership with Bukwang on its Atypical Antipsychotic Agent Lurasidone for Korea
  • Apr. 06, 2017 (PDF/53KB)Products
    Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of TRERIEF, a therapeutic agent for Parkinson's disease, in the Treatment of Patients with Parkinsonism in Dementia with Lewy Bodies (DLB)
  • Apr. 04, 2017 (PDF/347KB)Products
    Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
  • Mar. 30, 2017 (PDF/109KB)Products
    Toray Receives Japanese Approval for an Additional Formulation of Pruritus Treatment REMITCH OD TABLETS 2.5μg
  • Apr. 12, 2017 (PDF/81KB)R&D
    Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder (ADHD)
  • Apr. 07, 2017 (PDF/87KB)Licensing
    Sumitomo Dainippon Pharma Announces Partnership with Bukwang on its Atypical Antipsychotic Agent Lurasidone for Korea
  • Apr. 06, 2017 (PDF/53KB)Products
    Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of TRERIEF, a therapeutic agent for Parkinson's disease, in the Treatment of Patients with Parkinsonism in Dementia with Lewy Bodies (DLB)
  • Apr. 04, 2017 (PDF/347KB)Products
    Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
  • Mar. 30, 2017 (PDF/109KB)Products
    Toray Receives Japanese Approval for an Additional Formulation of Pruritus Treatment REMITCH OD TABLETS 2.5μg

more